Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Sanofi announces sale of 21.6 million shares held in Regeneron Gross proceeds of $11.1 billion to Sanofi to further Company’s ability to execute innovation and growth strategy PARIS – May 26 ...

Regeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY announced that the FDA has accepted for Priority Review the supplemental biologics license application (sBLA) seeking label expansion of ...

Sanofi controls 16.7 percent of Regeneron, or 15.82 million shares, according to Reuters data. Sanofi said in an email that it has the right to raise the stake to as much as 30 percent under its ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...